Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin.

ABSTRACT: Prevalence of diabetes mellitus is inc6reasing, with a burden of 382 million patients worldwide at present (more than the entire US population). The International Diabetes Federation anticipates an increase up to 592 million patients by 2035. Another major problem arises from the fact that just 50% of patients with type 2 diabetes mellitus are at target glycaemic control with currently available medications. Therefore, a clear need for new therapies that aim to optimize glycaemic control becomes evident. Renal sodium-linked glucose transporter 2 inhibitors are new antidiabetic drugs with an insulin-independent mechanism of action. They pose one remarkable advantage compared with already established antidiabetics: increasing urinary glucose excretion without inducing hypoglycaemia, thereby

SUBMITTER: Haas B 

PROVIDER: S-EPMC4259905 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature